Serum protein expression profiling in pediatric Hodgkin lymphoma: A report from the children's oncology group

Pediatric Blood and Cancer

Volumn 51, Issue 2, 2008, Pages 216-221

  Qi, Lining ^a   Cazares, Lisa ^a   Johnson, Cris ^b   De Alarcon, Pedro ^c,d   Kupfer, Gary M ^b,d,e   Semmes, O John ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d CHILDREN S ONCOLOGY GROUP   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hodgkin lymphoma; Pediatric oncology; Prognosis; Proteomics; Serum protein profiling; Staging

Indexed keywords

PROTEIN; ALPHA 1 ANTITRYPSIN; PLASMA PROTEIN;

ADOLESCENT; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CHILDHOOD CANCER; CLINICAL ARTICLE; DNA FINGERPRINTING; FEMALE; HODGKIN DISEASE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; SCHOOL CHILD; BLOOD; CHILD; MASS SPECTROMETRY; PATHOLOGY;

ADOLESCENT; ALPHA 1-ANTITRYPSIN; BLOOD PROTEINS; CHILD; FEMALE; HODGKIN DISEASE; HUMANS; MALE; NEOPLASM STAGING; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 45549105354     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21581     Document Type: Article

References (26)

1. Diehl V, Thomas RK, Re D. Part II: Hodgkin's lymphoma - Diagnosis and treatment. Lancet Oncol 2004;5:19-26.
2. Donaldson SS. A discourse: The 2002 Wataru W. Sutow lecture. Hodgkin disease in children - Perspectives and progress. Med Pediatr Oncol 2003;40:73-81.
3. Hutchinson RJ, Fryer CJ, Davis PC, et al. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: Results of the Children's Cancer Group Phase III Trial. J Clin Oncol 1998;16:897-906.
4. Schellong G, Potter R, Bramswig J, et al. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: The German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol 1999;17:3736-3744.
5. Dieckmann K, Potter R, Hofmann J, et al. Does bulky disease at diagnosis influence outcome in childhood Hodgkin's disease and require higher radiation doses? Results from the German-Austrian Pediatric Multicenter Trial DAL-HD-90. Int J Radiat Oncol Biol Phys 2003;56:644-652.
6. Prosnitz LR. The Ann Arbor staging system for Hodgkin's disease: Does E stand for error? Int J Radiat Oncol Biol Phys 1977;2:1039.
7. Rappaport H, Berard CW, Butler JJ, et al. Report of the committee on histopathological criteria contributing to staging of Hodgkin's disease. Cancer Res 1971;31:1864-1865.
8. Donaldson SS, Hudson MM, Lamborn KR, et al. VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: Results of a prospective clinical trial. J Clin Oncol 2002;20:3081-3087.
9. Nachman JB, Sposto R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 2002;20:3765-3771.
10. Schellong G, Bramswig JH, Hornig-Franz I, et al. Hodgkin's disease in children: Combined modality treatment for stages IA, IB, and IIA. Results in 356 patients of the German/Austrian Pediatric Study Group. Ann Oncol 1994;5:113-115.
11. Dorffel W, Luders H, Ruhl U, et al. Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: Analysis and outlook. Klin Padiatr 2003;215:139-145.
12. Hakvoort-Cammel FG, Buitendijk S, Heuvel-Eibrink M, et al. Treatment of pediatric Hodgkin disease avoiding radiotherapy: Excellent outcome with the Rotterdam-HD-84-protocol. Pediatr Blood Cancer 2004;43:8-16.
13. Tebbi CK, Mendenhall N, London WB, et al. Treatment of stage I, IIA, IIIA(1) pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: A Pediatric Oncology Group (POG) study. Pediatr Blood Cancer 2006;46:198-202.
14. Xiao Z, Prieto D, Conrads TP, et al. Proteomic patterns: Their potential for disease diagnosis. Mol Cell Endocrinol 2005;230:95-106.
15. Wright GL Jr. SELDI proteinchip MS: A platform for biomarker discovery and cancer diagnosis. Expert Rev Mol Diagn 2002;2:549-563.
16. Vitzthum F, Behrens F, Anderson NL, et al. Proteomics: From basic research to diagnostic application. A. review of requirements & needs. J Proteome Res 2005;4:1086-1097.
17. Seibert V, Ebert MP, Buschmann T. Advances in clinical cancer proteomics: SELDI-ToF-mass spectrometry and biomarker discovery. Brief Funct Genomic Proteomic 2005;4:16-26.
18. Adam BL, Qu Y, Davis JW, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002;62:3609-3614.
19. Li J, Zhang Z, Rosenzweig J, et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002;48:1296-1304.
20. Malik G, Ward MD, Gupta SK, et al. Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. Clin Cancer Res 2005;11:1073-1085.
21. Wadsworth JT, Somers KD, Stack BC Jr, et al. Identification of patients with head and neck cancer using serum protein profiles. Arch Otolaryngol Head Neck Surg 2004;130:98-104.
22. Semmes OJ, Cazares LH, Ward MD, et al. Discrete serum protein signatures discriminate between human retrovirus-associated hematologic and neurologic disease. Leukemia 2005;19:1229-1238.
23. Bertone P, Kluger Y, Lan N, et al. SPINE: An integrated tracking database and data mining approach for identifying feasible targets in high-throughput structural proteomics. Nucleic Acids Res 2001;29:2884-2898.
24. Kosuda S, Ichihara K, Watanabe M, et al. Decision-tree sensitivity analysis for cost-effectiveness of whole-body FDG PET in the management of patients with non-small-cell lung carcinoma in Japan. Ann Nucl Med 2002;16:263-271.
25. Hudson MM. Achieving cure for early stage pediatric Hodgkin disease with minimal morbidity: Are we there yet? Pediatr Blood Cancer 2006;46:122-126.
26. Lin HM, Teitell MA. Second malignancy after treatment of pediatric Hodgkin disease. J Pediatr Hematol Oncol 2005;27:28-36.